Volume 18, Issue 12, Pages (December 2016)

Slides:



Advertisements
Similar presentations
Volume 18, Issue 1, Pages (January 2016)
Advertisements

Introduction Conclusions
Δ-Tocotrienol treatment is more effective against hypoxic tumor cells than normoxic cells: potential implications for cancer therapy  Akira Shibata, Kiyotaka.
Cell Physiol Biochem 2013;32: DOI: /
PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.
Fig. 1. Effects of letrozole (Let; 10 μg/day) and tamoxifen (Tam; 100 μg/day) and their combined or alternating treatment on the growth of MCF-7Ca breast.
Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.
Volume 67, Issue 6, Pages (June 2015)
Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
A. B. BxPC-3 PANC h h h h h 100 *** * 72 h Cell viability (%) 80 *** *** Cell viability (%) 80 *** *** 60 *** ***
Li Ding, Lingling Han, Yin Li, Jing Zhao, Ping He, Weizhen Zhang 
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Fig. 4. TR3-dependent induction of ATF3 by DIM-C-pPhOCH 3 in human pancreatic cancer cells. ( A ) Induction of ATF3 by DIM-C-pPhOCH 3
Cell Physiol Biochem 2017;44:1867– DOI: /
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
Development of a Rab9 Transgenic Mouse and Its Ability to Increase the Lifespan of a Murine Model of Niemann-Pick Type C Disease  Tatiana Kaptzan, Sally.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
Vemurafenib Induces Senescence Features in Melanoma Cells
DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,
Molecular Therapy - Oncolytics
Volume 19, Issue 7, Pages (July 2017)
Supplementary Figure S13
Volume 19, Issue 3, Pages (March 2017)
Volume 144, Issue 2, Pages (February 2013)
Cancer-Specific Inhibitory Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-β Against Choriocarcinoma in Xenografted.
Volume 191, Issue 1, Pages (January 2014)
Volume 7, Issue 3, Pages (May 2014)
Volume 130, Issue 7, Pages (June 2006)
Volume 140, Issue 1, Pages (January 2011)
Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M
A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL  James.
Volume 19, Issue 3, Pages (March 2017)
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes  Kiyoko Setoguchi, Lin.
Volume 139, Issue 1, Pages (July 2010)
Volume 67, Issue 6, Pages (December 2017)
Volume 19, Issue 12, Pages (December 2017)
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
Volume 24, Issue 1, Pages (July 2013)
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Volume 26, Issue 2, Pages (August 2014)
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Volume 152, Issue 1, Pages (January 2019)
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models  Josephine Hai, PhD, Shingo Sakashita,
Volume 141, Issue 6, Pages e5 (December 2011)
AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer  Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,
Volume 22, Issue 3, Pages (March 2015)
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
Volume 27, Issue 1, Pages (January 2015)
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.
Molecular Therapy - Nucleic Acids
Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation  Yosuke.
Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines  Wei Zhang, PhD, Michael.
Volume 124, Issue 7, Pages (June 2003)
Volume 15, Issue 3, Pages (March 2009)
Molecular Therapy - Nucleic Acids
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance  Valeria R. Fantin, Julie St-Pierre,
EVA1A/TMEM166 Regulates Embryonic Neurogenesis by Autophagy
Volume 8, Issue 4, Pages (October 2005)
Volume 12, Issue 4, Pages (July 2015)
Volume 18, Issue 3, Pages (March 2010)
Comparison of a Treatment Strategy Combining CCI-779 Plus DTIC Versus DTIC Monotreatment in Human Melanoma in SCID Mice  Christiane Thallinger, Johannes.
Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer  Jun Young Park, Ye Lim Cho, Ju Ri Chae, Sung Hwan Moon,
Volume 20, Issue 4, Pages (April 2012)
A B HPAF-II CFPAC-1 cells Drug concentration, µM 50
A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
Presentation transcript:

Volume 18, Issue 12, Pages 765-774 (December 2016) Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42  Sally E. Henderson, Li-Yun Ding, Xiaokui Mo, Tanios Bekaii-Saab, Samuel K. Kulp, Ching-Shih Chen, Po-Hsien Huang  Neoplasia  Volume 18, Issue 12, Pages 765-774 (December 2016) DOI: 10.1016/j.neo.2016.10.003 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Antiproliferative effects of AR-42 in six different pancreatic cancer cell lines. Human PDAC cell lines (A) AsPC-1, (B) SW1990, (C) BxPC-3, (D) COLO-357, (E) MiaPaCa-2, and (F) PANC-1 were treated for 72 hours with AR-42 (Arno Therapeutics, Inc., Flemington, NJ). Cell viability was measured via MTT assay. The data are shown as mean ± SD of n = 6 replicates. Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Effects of AR-42 on various biomarkers of apoptosis, HDAC inhibition, and proliferation. Human PDAC cells (AsPC-1, SW1990, BxPC-3, COLO-357, and PANC-1) were treated with AR-42 for 48 hours at the concentrations indicated, and cell lysates were made for Western blotting. Immunoblots of markers of HDAC inhibition (A), apoptosis (B), and proliferation and G2 cell cycle arrest (C). β-Actin was used as a loading control. Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Effects of oral AR-42 in an AsPC-1 subcutaneous xenograft mouse model on tumor suppression and expression of intratumoral biomarkers of drug activity. Female athymic nude mice (5 weeks of age) were injected subcutaneously with 1 × 106 AsPC-1 cells. As the tumors became established (90.7 ± 9.4 mm3 [mean ± SD]), mice were treated with 50 mg/kg AR-42 (n = 7) or vehicle (n = 7) by oral gavage every other day. Tumor volume was measured weekly with calipers, and volumes were calculated with a standard formula: width2 × length x 0.52. (A) AR-42 reduced tumoral volume by 78% after 21 days of treatment (****P < .0001). (B) Effects of HDAC inhibition on representative intratumoral biomarkers of drug activity evaluated through Western immunoblotting of AsPC-1 tumor homogenates collected after 21 days of treatment. β-Actin was used as a loading control. Tumor volumes were analyzed by mixed effect model, incorporating repeated measures for each tumor (from day 0 to 21). Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions

Figure 4 Effects of oral AR-42 in a transgenic mouse model of pancreatic cancer. (A) KPfl/flC (LSL-KrasG12D;Trp53flox/flox;Pdx-1-Cre) genetically engineered mice at 4 weeks of age were treated with AR-42 at the 25- and 50-mg/kg dosage (n = 7 and 11, respectively) or vehicle (n = 11) by oral gavage every other day for 32 days. (B) Tumor volume was measured in mice using pancreatic ultrasound (Vevo 770) while mice were under anesthesia at weeks 4, 6, and 8. AR-42 (50 mg/kg) decreased the size of tumoral pancreas by 55% at week 8 (*P < .05). (C) Ex vivo pancreatic tumors were weighed postmortem at week 9. AR-42 decreased the total weight of the tumoral pancreas by 57.4% and 55.8% at the dosage of 25 and 50 mg/kg, respectively (****P < .0001). (D) Treatment with AR-42 significantly decreased the percent tumor area of the pancreas as evidenced by decreased pan-cytokeratin (AE1/AE3) immunostaining (*P < .05). (E) Immunofluorescence triple staining with pan-cytokeratin, Ki67, and active caspase 3. (F and G) The quantification of Ki67 and active caspase 3. Tumor weights were compared by using ANOVA; percent of Ki67+, percent tumor areas, and percent caspase 3 area were analyzed by two-sample t tests (*P < .05; ***P < .001). Note: n.s.: not significant. Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions

Figure 5 Kaplan-Meier survival curves. (A) Timeline of gemcitabine and AR-42 administration. (B) AR-42 alone (25 mg/kg [A25], p.o., every other day, n = 8 and 50 mg/kg [A50] p.o. every other day, n = 12), gemcitabine alone (40 mg/kg [G40] by i.p. injection twice weekly, n = 8 and 80 mg/kg [G80] by i.p. injection twice weekly; n = 7), and the combination of both gemcitabine and AR-42 (G40 + A25; n = 9) significantly increased survival in KPC mice compared to mice treated with vehicle (n = 16). The combination of AR-42 at 25 mg/kg and gemcitabine at 40 mg/kg significantly increased the median survival time (83 days) relative to AR-42 (P < .0001) and gemcitabine (P < .05) alone. Statistical comparison of survival curves was performed with log-rank test (*P < .05; **P < .01; ****P < .0001). Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions

Figure 6 Anticachectic effects of oral AR-42. (A) Upper panel, photographic images of representative leg skeletal muscles in the right hind limb; lower panel, H&E staining of represented frozen cross-sectional gastrocnemius muscle fibers of KPfl/flC mice treated with AR-42 (25 mg/kg) or vehicle. (B) The cross-sectional area of muscle fiber diameter is represented as a stacked column. The number of fibers >1800μm2 in gastrocnemius muscles in KPfl/flC mice treated with AR-42 (25 mg/kg) was significantly greater than vehicle-treated mice (***P < .001, χ2 test). (C) Treatment with AR-42 resulted in a significant improvement in grip strength from week 4 to week 8 (*P < .05), whereas vehicle-treated mice showed a significant decrease in grip strength from week 4 to week 8 (*P < .05). Grip strength was significantly increased in the AR-42–treated group versus vehicle at week 8 in KPfl/flC mice (**P < .01). (D) Treatment with AR-42 resulted in decreased expression of the cachexia biomarker MuRF1 and increased expression of the HDAC inhibition marker acetylated histone H3. Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions

Supplementary Figure S1. Effects of AR-42 on cell cycle. Pancreatic cancer cells were treated with vehicle control and 0.5 μM AR-42 (AsPC-1, BxPC-3, COLO-357, SW1990, and MiaPaCa-2) or 2 μM AR-42 (PANC-1) for 48 hours. Cells were harvested, stained with propodium iodide, and analyzed through fluorescence-activated cell sorting. The percent of cells in Sub-G1, G0/G1, S, and G2/M cell cycle phase is shown. Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions

Supplementary Figure S2. AR-42 preserved the hindlimb skeletal muscles. Neoplasia 2016 18, 765-774DOI: (10.1016/j.neo.2016.10.003) Copyright © 2016 The Authors Terms and Conditions